MCID: PNC013
MIFTS: 44

Pancreatic Ductal Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Ductal Carcinoma

MalaCards integrated aliases for Pancreatic Ductal Carcinoma:

Name: Pancreatic Ductal Carcinoma 12 15
Carcinoma, Pancreatic Ductal 44 72
Malignant Neoplasm of Duct of Wirsung 12
Carcinoma Pancreatic Ductal 55
Pancreatic Duct Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3587
ICD9CM 35 157.3
MeSH 44 D021441
SNOMED-CT 68 93939009
ICD10 33 C25.3
UMLS 72 C0153461 C0887833

Summaries for Pancreatic Ductal Carcinoma

Disease Ontology : 12 A pancreatic carcinoma located in the pancreatic duct.

MalaCards based summary : Pancreatic Ductal Carcinoma, also known as carcinoma, pancreatic ductal, is related to microcystic adenoma and mucoepidermoid carcinoma. An important gene associated with Pancreatic Ductal Carcinoma is MUC6 (Mucin 6, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Axitinib and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and lung, and related phenotypes are cellular and homeostasis/metabolism

Related Diseases for Pancreatic Ductal Carcinoma

Diseases related to Pancreatic Ductal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 264)
# Related Disease Score Top Affiliating Genes
1 microcystic adenoma 30.9 MUC6 MUC1
2 mucoepidermoid carcinoma 30.4 MUC2 MUC1 KRT7
3 tubular adenocarcinoma 30.4 MUC2 MUC1 KRT20
4 neuroendocrine tumor 29.9 NTS KRT7 KRT20
5 papillary adenocarcinoma 29.8 TP53 MUC2 MUC1 KRT7
6 mesothelioma, malignant 29.8 MUC1 KRT7 KRT20 CDKN2A
7 cystadenoma 29.6 MUC6 MUC2 MUC1 KRT7 KRT20
8 acinar cell carcinoma 29.5 TP53 SMAD4 KRT7
9 ovarian cancer 29.5 VEGFA TP53 MUC2 MUC1 KRT7
10 cystadenocarcinoma 29.4 VEGFA TP53 MUC2 MUC1 KRT7
11 adenocarcinoma 29.3 VEGFA TP53 SMAD4 MUC1 CDKN2A
12 pancreatic cancer 28.2 VEGFA TP53 SMAD4 NTS MUC2 MUC1
13 lung cancer susceptibility 3 27.0 VEGFA TYMP TP53 SMAD4 MUC1 KRT7
14 pancreatic adenosquamous carcinoma 11.4
15 endosalpingiosis 10.7 MUC1 KRT7
16 middle ear adenoma 10.7 MUC1 KRT7
17 secretory meningioma 10.7 MUC1 KRT7
18 parachordoma 10.7 MUC1 KRT7
19 nodular hidradenoma 10.7 MUC1 KRT7
20 hidradenoma 10.6 MUC1 KRT7
21 monophasic synovial sarcoma 10.6 MUC1 KRT7
22 cystic basal cell carcinoma 10.6 KRT7 KRT20
23 malignant syringoma 10.6 KRT7 KRT20
24 appendix adenocarcinoma 10.6 KRT7 KRT20
25 transverse colon cancer 10.6 KRT7 KRT20
26 seminal vesicle adenocarcinoma 10.6 KRT7 KRT20
27 pancreatic ductal adenocarcinoma 10.6
28 krukenberg carcinoma 10.6 KRT7 KRT20
29 papillary transitional carcinoma 10.6 KRT7 KRT20
30 glandular cystitis 10.6 KRT7 KRT20
31 small cell carcinoma of the bladder 10.6 KRT7 KRT20
32 lung acinar adenocarcinoma 10.6 KRT7 KRT20
33 linitis plastica 10.6 KRT7 KRT20
34 large intestine adenocarcinoma 10.6 KRT7 KRT20
35 intratubular embryonal carcinoma 10.6 KRT7 KRT20
36 adenoid squamous cell carcinoma 10.6 KRT7 KRT20
37 pancreatic serous cystadenoma 10.6 VEGFA KRT7
38 mucinous intrahepatic cholangiocarcinoma 10.6 MUC6 MUC2
39 meibomian cyst 10.6 KRT7 KRT20
40 gastric diffuse adenocarcinoma 10.6 KRT7 KRT20
41 thymus adenocarcinoma 10.6 KRT7 KRT20
42 small intestine adenocarcinoma 10.6 MUC6 MUC2
43 mucinous ovarian cystadenoma 10.6 MUC1 KRT7
44 jejunal adenocarcinoma 10.6 KRT7 KRT20
45 bladder adenocarcinoma 10.5 KRT7 KRT20
46 bladder lymphoma 10.5 KRT7 KRT20
47 tn polyagglutination syndrome 10.5 MUC2 MUC1
48 chronic cystitis 10.5 KRT7 KRT20
49 medulloepithelioma 10.5 KRT7 KRT20
50 malignant spiradenoma 10.5 TP53 KRT7

Graphical network of the top 20 diseases related to Pancreatic Ductal Carcinoma:



Diseases related to Pancreatic Ductal Carcinoma

Symptoms & Phenotypes for Pancreatic Ductal Carcinoma

MGI Mouse Phenotypes related to Pancreatic Ductal Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.76 CDKN2A KRT7 MUC2 SMAD4 TGM2 TP53
2 homeostasis/metabolism MP:0005376 9.61 CDKN2A KRT7 MUC2 NTS SMAD4 TGM2
3 neoplasm MP:0002006 9.1 CDKN2A MUC2 SMAD4 TGM2 TP53 VEGFA

Drugs & Therapeutics for Pancreatic Ductal Carcinoma

Drugs for Pancreatic Ductal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Axitinib Approved, Investigational Phase 3 319460-85-0 6450551
2
Gemcitabine Approved Phase 3 95058-81-4 60750
3
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
4
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
5 Protein Kinase Inhibitors Phase 3
6 Antineoplastic Agents, Phytogenic Phase 3
7 Anti-Infective Agents Phase 3
8 Tubulin Modulators Phase 3
9 Albumin-Bound Paclitaxel Phase 3
10 Immunosuppressive Agents Phase 3
11 Antimitotic Agents Phase 3
12 Antimetabolites, Antineoplastic Phase 3
13 Antiviral Agents Phase 3
14 Immunologic Factors Phase 3
15 Antimetabolites Phase 3
16 Adjuvants, Immunologic Phase 3
17 Viscosupplements Phase 3
18
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
19
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
21
Enoxaparin Approved Phase 2 9005-49-6 772
22
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
23
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
24
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
25
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
26
Fluorouracil Approved Phase 2 51-21-8 3385
27
leucovorin Approved Phase 2 58-05-9 143 6006
28
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
29
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
30
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
31
Apaziquone Investigational Phase 1, Phase 2 114560-48-4 5813717
32
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
33 Antibodies Phase 2
34 Antibodies, Monoclonal Phase 2
35 Immunoglobulins Phase 2
36 Gastrointestinal Agents Phase 2
37 Antineoplastic Agents, Immunological Phase 2
38 Peripheral Nervous System Agents Phase 2
39 Autonomic Agents Phase 2
40 Pharmaceutical Solutions Phase 2
41 Hormone Antagonists Phase 2
42 Antiemetics Phase 2
43 HIV Protease Inhibitors Phase 2
44
protease inhibitors Phase 2
45 Anti-Inflammatory Agents Phase 2
46 glucocorticoids Phase 2
47 Hormones Phase 2
48 Antineoplastic Agents, Hormonal Phase 2
49 BB 1101 Phase 2
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer. Completed NCT00471146 Phase 3 AG-013736;Gemcitabine;Gemcitabine;placebo
2 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Active, not recruiting NCT02715804 Phase 3 Placebo;nab-Paclitaxel;Gemcitabine
3 A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
4 Phase II Study of Chemotherapy Selection Based on Therapeutic Targets for the Treatment of Advanced Pancreatic Cancer Unknown status NCT01394120 Phase 2 Targeted Therapy Tailored Treatment;Standard Chemotherapy
5 A Multicenter Phase II Trial of Weekly Gemcitabine, Paclitaxel, and Hyperfractionated External Irradiation (63.80 GY) for Locally Advanced Pancreatic Cancer Completed NCT00226746 Phase 2 Paclitaxel and gemcitabine
6 A Non-controlled, Single Arm, Open Label, Phase II Study of Intravenous and Intratumoral Administration of ParvOryx in Patients With Metastatic, Inoperable Pancreatic Cancer Completed NCT02653313 Phase 1, Phase 2 Parvovirus H-1 (H-1PV)
7 A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer Completed NCT00902291 Phase 2
8 A PHASE Ib/IIa STUDY OF COMBINATION THERAPY WITH GEMCITABINE AND ATU027 IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA Completed NCT01808638 Phase 1, Phase 2 Atu027 & gemcitabine in lead in safety period;Atu027 & gemcitabine in treatment arm 1;Atu027 & gemcitabine in treatment arm 2
9 An Open-Label Phase 2 Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002 Completed NCT01608711 Phase 2
10 A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer Completed NCT01839487 Phase 2 PEGPH20;Nab-paclitaxel;Gemcitabine;Dexamethasone;Enoxaparin
11 A Multicenter, Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) in Subjects With Advanced or Unresectable Pancreatic Ductal Carcinoma Whose Tumors Have Progressed Following Prior Treatment With Gemcitabine and Fluoropyrimidine-Based Chemotherapy Completed NCT01580397 Phase 2 INNO-206
12 Panitumumab in Combination With Cisplatin/Gemcitabine Chemotherapy in Patients With Cholangiocarcinomas - a Randomized Clinical Phase II Study Completed NCT01320254 Phase 2 Cisplatin, Gemcitabine, Panitumumab;Cisplatin, Gemcitabine
13 Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer Recruiting NCT02529579 Phase 1, Phase 2 Gemcitabine
14 A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of the Combination of S-1, Irinotecan and Oxaliplatin (SIRIOX) in Treating Patients With Advanced Inoperable or Metastatic Pancreatic Cancer Recruiting NCT03403101 Phase 2 S1;Oxaliplatin;Irinotecan
15 Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic Cancer Recruiting NCT03977233 Phase 2 Oxaliplatin;Leucovorin;Irinotecan Hydrochloride;5-FU
16 Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer Terminated NCT02243007 Phase 2 FOLFIRINOX;Gemcitabine/nab-Paclitaxel;Capecitabine
17 A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors Completed NCT01478685 Phase 1 CC-486;Carboplatin;ABI-007
18 A Phase IB Trial With OTX015/MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors Completed NCT02259114 Phase 1 MK-8628
19 A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors. Active, not recruiting NCT02658214 Phase 1 paclitaxel + carboplatin;carboplatin + etoposide;gemcitabine + carboplatin;nab-paclitaxel (paclitaxel-albumin) + carboplatin;oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid);nab-paclitaxel (paclitaxel-albumin) + gemcitabine;cisplatin + 5-fluorouracil (5FU)
20 A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02231723 Phase 1 BBI608;Nab-paclitaxel;Gemcitabine;Oxaliplatin;Leucovorin;Irinotecan;Fluorouracil;MM-398
21 A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors Active, not recruiting NCT02646748 Phase 1 Pembrolizumab;itacitinib;INCB050465
22 A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors Not yet recruiting NCT04045496 Phase 1 JAB-3312
23 To Compare the Influences of Different Methods to Remove the Pancreatic Ductal Adenocarcinoma With the Detection of Circulating Tumor Cells Unknown status NCT02451384
24 An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy Unknown status NCT02310230
25 CT Perfusion of Pancreatic Cancer and Chronic Pancreatitis: Feasibility Study Completed NCT00588367
26 Continuous Monitoring of Vital Signs in Hospitalized Patients Completed NCT02933307
27 Circulating Tumor Cells Shed in Operative Blood During Pancreatectomy for Pancreatic Cancer is Responsible for Peritoneal Recurrence Completed NCT02150746
28 Prospective Populationbased Study on Pancreatic Cancer in Stockholm- Mutation Profiling Characteristics, Biobanking and Risk Factors. Completed NCT02162823
29 Endoscopic Retrograde CholangioPancreatography Endomicroscopy Registry Outcomes Database Completed NCT00779688
30 Comprehensive Molecular Characterization of Advanced Pancreatic Ductal Adenocarcinomas (PDAC) for Better Treatment Selection: A Prospective Study Recruiting NCT02750657
31 Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas Recruiting NCT02817308
32 Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy Recruiting NCT02928081
33 Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1): a Multicenter Stepped-wedge Cluster Randomized Controlled Trial Recruiting NCT03513705
34 Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study Recruiting NCT03500068
35 Irreversible Electroporation for Locally Advanced Pancreatic Ductal Adenocarcinoma (LEAP TRIAL): A Phase I/II Prospective Trial Recruiting NCT03257150 18F-Fluoroazomycin arabinoside
36 A Clinical Validation Study on the Efficacy of MicroRNA-25 Level Detection in Assisting the Diagnosis of Pancreatic Cancer Not yet recruiting NCT03432624
37 Evaluation of Safety and Feasibility of Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA) for Solid Pancreatic Neoplasms Not yet recruiting NCT03435770
38 A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers Terminated NCT01413451 Early Phase 1 Amatuximab (MORab-009)
39 Role of Adrenomedullin in Early Diagnosis of Pancreatic Cancer in New Onset Diabetes Patients Terminated NCT02456051

Search NIH Clinical Center for Pancreatic Ductal Carcinoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


gemcitabine
Gemcitabine hydrochloride

Cochrane evidence based reviews: carcinoma, pancreatic ductal

Genetic Tests for Pancreatic Ductal Carcinoma

Anatomical Context for Pancreatic Ductal Carcinoma

MalaCards organs/tissues related to Pancreatic Ductal Carcinoma:

41
Pancreas, Liver, Lung, Prostate, Lymph Node, Endothelial, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreatic Ductal Carcinoma:

19
Pancreatic Duct

Publications for Pancreatic Ductal Carcinoma

Articles related to Pancreatic Ductal Carcinoma:

(show top 50) (show all 330)
# Title Authors PMID Year
1
Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. 9 38
16951195 2006
2
Intercalated duct cell is starting point in development of pancreatic ductal carcinoma? 9 38
16018800 2005
3
Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. 9 38
15725805 2005
4
The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma. 9 38
15084978 2004
5
MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration. 9 38
14681945 2003
6
Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. 9 38
12717266 2003
7
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. 9 38
11787853 2001
8
Exclusion of SMAD4 mutation as an early genetic change in human pancreatic ductal tumorigenesis. 9 38
11391801 2001
9
Pancreatic intraepithelial neoplasia and infiltrating adenocarcinoma: analysis of progression and recurrence by DPC4 immunohistochemical labeling. 9 38
11431719 2001
10
Heterogeneic distribution of thymidine phosphorylase between primary tumors and metastatic lesions of human pancreatic ductal carcinoma: implications for the efficacy of chemotherapy with 5-FU or its derivatives. 9 38
11391857 2001
11
Mutational Patterns in Pancreatic Juice of Intraductal Papillary Mucinous Neoplasms and Concomitant Pancreatic Cancer. 38
31404021 2019
12
ILF2 promotes anchorage independence through direct regulation of PTEN. 38
31423236 2019
13
Primary non-ampullary duodenal follicular lymphoma presenting with obstructive jaundice. 38
31401784 2019
14
Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis. 38
31148345 2019
15
MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with 99mTc(I) Tricarbonyl Complex. 38
31242384 2019
16
Evaluation of a biomarker for the diagnosis of pancreas cancer using an animal model. 38
31404387 2019
17
[MicroRNA-21 correlates TGF-β1 pathway of pancreatic ductal adenocarcinoma]. 38
31413212 2019
18
Predictive Factors for Elevated Postoperative Carbohydrate Antigen 19-9 Levels in Patients With Resected Pancreatic Cancer. 38
31177164 2019
19
The Sustained Induction of c-MYC Drives Nab-paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. 38
31164413 2019
20
Organoid-based ex vivo reconstitution of Kras-driven pancreatic ductal carcinogenesis. 38
31233118 2019
21
Mixed ductal-acinar cell carcinoma of the pancreas: A case report. 38
30967946 2019
22
Reduction of intrapancreatic neural density in cancer tissue predicts poorer outcome in pancreatic ductal carcinoma. 38
30776178 2019
23
[A Case Report of Conversion Surgery for Pancreatic Ductal Adenocarcinoma with Liver Metastasis after Chemotherapy]. 38
31164541 2019
24
Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells. 38
30898113 2019
25
Diabetes of the exocrine pancreas. 38
30151918 2019
26
Invasive Ductal Carcinoma Arising in Mucinous Cystic Neoplasm of Pancreas: A Case Report. 38
30798329 2019
27
Prognostic Value of MicroRNA-15a in Human Cancers: A Meta-Analysis and Bioinformatics. 38
31061821 2019
28
Clinical impact of margin status on survival and recurrence pattern after curative-intent surgery for pancreatic cancer. 38
29249392 2019
29
Clinical impact of different exosomes' protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy. 38
31048929 2019
30
An Autopsy Case of Anaplastic Pancreatic Ductal Carcinoma (Spindle Cell Type) Multiple Onset in the Pancreas. 38
31123460 2019
31
Prognostic significance of circulating microRNA-21 expression in esophageal, pancreatic and colorectal cancers; a systematic review and meta-analysis. 38
30336280 2018
32
Porphyrins to restrict progression of pancreatic cancer by stabilizing KRAS G-quadruplex: In silico, in vitro and in vivo validation of anticancer strategy. 38
30223034 2018
33
Anaplastic pancreatic cancer diagnosed with endoscopic ultrasound guided fine needle aspiration showing hypervascular tumor: A case report. 38
30544436 2018
34
Small pancreatic ductal carcinomas on triple-phase contrast-enhanced computed tomography: enhanced rims and the pathologic correlation. 38
29796845 2018
35
Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure. 38
30515264 2018
36
Routine MRI With DWI Sequences to Detect Liver Metastases in Patients With Potentially Resectable Pancreatic Ductal Carcinoma and Normal Liver CT: A Prospective Multicenter Study. 38
30240298 2018
37
A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort. 38
30326968 2018
38
Mast cells and angiogenesis in pancreatic ductal adenocarcinoma. 38
29492715 2018
39
Assessment of pancreatic colloid carcinoma using 18F-FDG PET/CT compared with MRI and enhanced CT. 38
30008837 2018
40
Role of staging laparoscopy in the management of Pancreatic Duct Carcinoma (PDAC): Single-center experience from a tertiary hospital in Brazil. 38
29509968 2018
41
The prognostic value of CXC chemokine receptor 2 (CXCR2) in cancers: a meta-analysis. 38
29599927 2018
42
Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report. 38
29409514 2018
43
Expression of UGP2 and CFL1 expression levels in benign and malignant pancreatic lesions and their clinicopathological significance. 38
29347944 2018
44
Frozen section examination of pancreas, gallbladder, extrahepatic biliary tree, liver, and gastrointestinal tract. 38
30441965 2018
45
GATA4 inhibits cell differentiation and proliferation in pancreatic cancer. 38
30142155 2018
46
[A Resectable Case of TS-1 Therapy Useful in Distinguishing Primary Lung Cancer from Lung Metastases of Pancreatic Cancer]. 38
29362317 2018
47
Worsened outcome in patients with pancreatic ductal carcinoma on long-term diabetes: association with E-cadherin1 (CDH1) promoter methylation. 38
29273724 2017
48
Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma. 38
29254283 2017
49
[An Enhanced Multimodality Treatment Strategy in Pancreatic Ductal Carcinoma Requiring Heminephrectomy for Radical Resection - A Case Report]. 38
29394636 2017
50
Intestinal autotransplantation. 38
29230296 2017

Variations for Pancreatic Ductal Carcinoma

Expression for Pancreatic Ductal Carcinoma

Search GEO for disease gene expression data for Pancreatic Ductal Carcinoma.

Pathways for Pancreatic Ductal Carcinoma

GO Terms for Pancreatic Ductal Carcinoma

Cellular components related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi lumen GO:0005796 8.8 MUC6 MUC2 MUC1

Biological processes related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell growth GO:0030308 9.54 TP53 SMAD4 CDKN2A
2 maintenance of gastrointestinal epithelium GO:0030277 9.32 MUC6 MUC2
3 replicative senescence GO:0090399 9.26 TP53 CDKN2A
4 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.16 TP53 MUC1
5 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.13 MUC6 MUC2 MUC1
6 O-glycan processing GO:0016266 8.8 MUC6 MUC2 MUC1

Sources for Pancreatic Ductal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....